AR111494A1 - Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer - Google Patents
Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncerInfo
- Publication number
- AR111494A1 AR111494A1 ARP180101102A ARP180101102A AR111494A1 AR 111494 A1 AR111494 A1 AR 111494A1 AR P180101102 A ARP180101102 A AR P180101102A AR P180101102 A ARP180101102 A AR P180101102A AR 111494 A1 AR111494 A1 AR 111494A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- anilinoquinazoline
- compounds
- cancer treatment
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490859P | 2017-04-27 | 2017-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111494A1 true AR111494A1 (es) | 2019-07-17 |
Family
ID=62091877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101102A AR111494A1 (es) | 2017-04-27 | 2018-04-27 | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10273227B2 (https=) |
| EP (1) | EP3615522B1 (https=) |
| JP (1) | JP7128204B2 (https=) |
| KR (1) | KR102603153B1 (https=) |
| CN (1) | CN110573505B (https=) |
| AR (1) | AR111494A1 (https=) |
| AU (1) | AU2018259078B2 (https=) |
| CA (1) | CA3059283A1 (https=) |
| ES (1) | ES2888298T3 (https=) |
| MX (1) | MX389244B (https=) |
| RU (1) | RU2769694C2 (https=) |
| TW (1) | TWI774758B (https=) |
| WO (1) | WO2018197642A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7128204B2 (ja) * | 2017-04-27 | 2022-08-30 | アストラゼネカ・アクチエボラーグ | Ｃ５－アニリノキナゾリン化合物及び癌の処置におけるそれらの使用 |
| EP3867280A4 (en) * | 2018-10-18 | 2022-11-09 | Sinomab Bioscience Limited | METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS |
| AR117788A1 (es) * | 2019-01-14 | 2021-08-25 | Pi Industries Ltd | Compuestos de fenilamidina 3-sustituida, preparación y uso |
| MX2022013797A (es) | 2020-05-08 | 2022-11-30 | Genmab As | Anticuerpos biespecificos contra cd3 y cd20. |
| WO2022040341A1 (en) * | 2020-08-20 | 2022-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Abscopal therapy for cancer |
| CN116782933A (zh) | 2020-09-10 | 2023-09-19 | 健玛保 | 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
| KR20230066040A (ko) | 2020-09-10 | 2023-05-12 | 젠맵 에이/에스 | 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체 |
| CA3189883A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| CA3190376A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| US20240034812A1 (en) | 2020-09-10 | 2024-02-01 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| TW202345831A (zh) * | 2021-12-09 | 2023-12-01 | 美商迪賽孚爾製藥有限公司 | Ｋｉｔ激酶抑制劑及其使用方法 |
| US20250275978A1 (en) * | 2024-03-04 | 2025-09-04 | Cardiff Oncology, Inc. | Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| CA2384291A1 (en) | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
| DK1382604T3 (da) | 2001-04-27 | 2006-04-18 | Kirin Brewery | Quinolinderivater med en azolylgruppe og quinazolinderivater |
| TW200505452A (en) * | 2003-06-17 | 2005-02-16 | Astrazeneca Ab | Chemical compounds |
| EP1684762A4 (en) * | 2003-11-13 | 2009-06-17 | Ambit Biosciences Corp | UREA DERIVATIVES AS MODULATORS OF KINASE |
| BRPI0516093A (pt) | 2004-10-12 | 2008-08-19 | Astrazeneca Ab | derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US20070106549A1 (en) | 2005-11-04 | 2007-05-10 | Stocking Christine A | Turnkey aviation budget management |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| WO2008089310A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of obesity |
| US20080194557A1 (en) | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| AU2009246263B2 (en) | 2008-05-14 | 2014-08-21 | Amgen Inc. | Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| CN102532042A (zh) * | 2010-12-30 | 2012-07-04 | 上海医药工业研究院 | 一种芳基脲类化合物、其中间体及其应用 |
| WO2012155339A1 (zh) * | 2011-05-17 | 2012-11-22 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| CN103254142B (zh) | 2013-04-26 | 2015-10-28 | 浙江工业大学 | 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用 |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| CN104130200B (zh) | 2014-07-01 | 2016-04-20 | 中山大学 | 一种2-取代苯基-4-芳胺基喹唑啉衍生物及其制备方法和应用 |
| JP7128204B2 (ja) * | 2017-04-27 | 2022-08-30 | アストラゼネカ・アクチエボラーグ | Ｃ５－アニリノキナゾリン化合物及び癌の処置におけるそれらの使用 |
| WO2018197643A1 (en) | 2017-04-27 | 2018-11-01 | Astrazeneca Ab | Phenoxyquinazoline compounds and their use in treating cancer |
-
2018
- 2018-04-26 JP JP2019557764A patent/JP7128204B2/ja active Active
- 2018-04-26 KR KR1020197034070A patent/KR102603153B1/ko active Active
- 2018-04-26 CN CN201880027620.0A patent/CN110573505B/zh active Active
- 2018-04-26 CA CA3059283A patent/CA3059283A1/en active Pending
- 2018-04-26 EP EP18721348.3A patent/EP3615522B1/en active Active
- 2018-04-26 MX MX2019012847A patent/MX389244B/es unknown
- 2018-04-26 US US15/963,122 patent/US10273227B2/en active Active
- 2018-04-26 TW TW107114297A patent/TWI774758B/zh active
- 2018-04-26 AU AU2018259078A patent/AU2018259078B2/en active Active
- 2018-04-26 ES ES18721348T patent/ES2888298T3/es active Active
- 2018-04-26 RU RU2019136279A patent/RU2769694C2/ru active
- 2018-04-26 WO PCT/EP2018/060798 patent/WO2018197642A1/en not_active Ceased
- 2018-04-27 AR ARP180101102A patent/AR111494A1/es active IP Right Grant
-
2019
- 2019-03-05 US US16/292,817 patent/US10829479B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3059283A1 (en) | 2018-11-01 |
| US20180312490A1 (en) | 2018-11-01 |
| MX389244B (es) | 2025-03-20 |
| CN110573505B (zh) | 2023-04-11 |
| BR112019022229A2 (pt) | 2020-05-12 |
| JP7128204B2 (ja) | 2022-08-30 |
| RU2019136279A (ru) | 2021-05-27 |
| RU2019136279A3 (https=) | 2021-05-31 |
| ES2888298T3 (es) | 2022-01-03 |
| AU2018259078A1 (en) | 2019-10-17 |
| JP2020517677A (ja) | 2020-06-18 |
| RU2769694C2 (ru) | 2022-04-05 |
| EP3615522A1 (en) | 2020-03-04 |
| TWI774758B (zh) | 2022-08-21 |
| EP3615522B1 (en) | 2021-08-04 |
| MX2019012847A (es) | 2022-01-07 |
| TW201904960A (zh) | 2019-02-01 |
| AU2018259078B2 (en) | 2021-10-07 |
| US20190263787A1 (en) | 2019-08-29 |
| US10273227B2 (en) | 2019-04-30 |
| WO2018197642A1 (en) | 2018-11-01 |
| US10829479B2 (en) | 2020-11-10 |
| KR20190141203A (ko) | 2019-12-23 |
| CN110573505A (zh) | 2019-12-13 |
| KR102603153B1 (ko) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| AR114971A1 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
| AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
| AR100340A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| AR094784A1 (es) | Compuestos de tubulisina, métodos para obtenerlos y uso | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| AR097325A1 (es) | Pirroles anillados | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR112086A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR093937A1 (es) | Compuestos quimicos | |
| AR094553A1 (es) | Formas de oxadiazolpirazina | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR101479A1 (es) | Derivados de 6-alquinil-piridina | |
| AR109706A1 (es) | INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g | |
| AR098723A1 (es) | Derivados de pirazolopirimidin-2-ilo como inhibidores de jak |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |